| 1999年 | 金沢大学医学部医学科卒業 |
|---|---|
| 同年 | 金沢大学医学部 第二外科学教室 |
| 2008年 | 医学博士 (金沢大学大学院医学系研究科 外科学専攻) |
| 2009年 | がん研有明病院 |
| 2011年 | 東京大学医学部附属病院 肝胆膵外科・人工臓器移植外科 助教 |
| 2015年 | 東京オンコロジークリニック 院長 |
| 2019年 | 順天堂大学医学部附属順天堂医院 肝胆膵外科 非常勤講師 |
| 2021年 | 東京目白クリニック 院長 |
取得資格
- 医学博士
- 日本外科学会認定 外科専門医
- 日本消化器外科学会認定 消化器外科専門医
- 日本臨床腫瘍学会認定 がん薬物療法専門医
- 日本消化器内視鏡学会認定 消化器内視鏡専門医
- 日本消化器病学会認定 消化器病専門医
- 日本肝臓学会認定 肝臓専門医
- 日本外科学会認定 指導医
- 日本消化器外科学会認定 指導医
- 日本臨床腫瘍学会認定 指導医
- 日本消化器病学会認定 指導医
- 日本がん治療認定医機構 がん治療認定医
- 消化器がん外科治療認定医
- がん等の診療に携わる医師等に対する緩和ケア研修会修了
- 東京都難病指定医
- 順天堂大学医学部附属順天堂医院 肝胆膵外科 非常勤講師
主な英語論文業績（和文業績は数多あり省略）
世界中で特に引用数の多い英語論文
- Discrepancy between recurrence-free survival and overall survival in patients with resectable colorectal liver metastases: a potential surrogate endpoint for time to surgical failure
- Ann Surg Oncol 2014; 21: 1817-1824.
- 論文ファイル
- Survival benefit of repeat resection of successive recurrences after the initial hepatic resection for colorectal liver metastases
- Surgery 2016; 159: 632-640.
- 論文ファイル
ほか主な英語論文
- Feasibility of major hepatectomy following preoperative chemotherapy for advanced perihilar cholangiocarcinoma
- Eur J Surg Oncol 2024; DOI: 10.1016/j.ejso.2024.108733.https://pubmed.ncbi.nlm.nih.gov/39419746/
- Sequential therapy of portal vein embolization and systemic chemotherapy for locally advanced perihilar biliary tract cancer
- Eur J Surg Oncol 2023; DOI: 10.1016/j.ejso.2023.08.035https://pubmed.ncbi.nlm.nih.gov/36089453/
- A randomized controlled trial of surgery and postoperative modified FOLFOX6 versus surgery and perioperative modified FOLFOX6 plus cetuximab in patients with KRAS wild-type resectable colorectal liver metastases: EXPERT study
- Langenbecks Arch Surg; 2022 DOI:https://doi.org/10.1007/s00423-022-02434-7
- A multicenter phase II trial evaluating the efficacy of bevacizumab plus mFOLFOX6 for R0 surgical resection in advanced colorectal liver metastases harboring mutant-type KRAS: NEXTO-mt trial
- HPB (Oxford); 2022 DOI:https://doi.org/10.1016/j.hpb.2022.02.001
- Adjuvant chemotherapy can prolong recurrence-free survival but did not
influence the type of recurrence or subsequent treatment in patients
with colorectal liver metastases - Surgery 2021; DOI:https://doi.org/10.1016/j.surg.2021.04.012
- A Multicenter Phase 2 Trial to Evaluate the Efficacy of mFOLFOX6 + Cetuximab as Induction Chemotherapy to Achieve R0 Surgical Resection for Advanced Colorectal Liver Metastases (NEXTO Trial)
- Ann Surg Oncol 2020; 27: 4188-4195.
- Adjuvant Oral Uracil-Tegafur with Leucovorin for Colorectal Cancer Liver Metastases: A Randomized Controlled Trial
- PLoS One 2016; 11: e0162400.
- Phase 1 study on S-1 and oxaliplatin therapy as an adjuvant after hepatectomy for colorectal liver metastases
- Invest New Drugs 2016; 34: 468-473.
- CD133 Expression at the Metastatic Site Predicts Patients’ Outcome in Colorectal Cancer with Synchronous Liver Metastasis
- Ann Surg Oncol 2016; 23: 1916-1923.
- Repeat resection leads to long-term survival: analysis of 10-year follow-up of patients with colorectal liver metastases
- Am J Surg 2015; 210: 904-910.
- Radiological Morphology of Colorectal Liver Metastases after Preoperative Chemotherapy Predicts Tumor Viability and Postoperative Outcomes
- J Gastrointest Surg 2015; 19: 1653-1661.
- Cetuximab treatment for metastatic colorectal cancer with KRAS p.G13D mutations improves progression-free survival
- Mol Clin Oncol 2015; 3: 1053-1057.
- Cetuximab for resectable colorectal liver metastasis: new EPOC trial
- Lancet Oncol 2014; 15: e305-306.
- Evaluation of the safety and efficacy of simultaneous resection of primary colorectal cancer and synchronous colorectal liver metastases
- Surgery 2014; 155: 478-485.
- Surgical resection for local recurrence after radiofrequency ablation for colorectal liver metastasis is more extensive than primary resection
- Scand J Gastroenterol 2014; 49: 569-575.
- A combination of oral uracil-tegafur plus leucovorin (UFT + LV) is a safe regimen for adjuvant chemotherapy after hepatectomy in patients with colorectal cancer: safety report of the UFT/LV study
- Drug Discov Ther 2014; 8: 48-56.
- Perioperative chemotherapy and liver resection for hepatic metastases
of colorectal cancer - J Hepatobiliary Pancreat Sci 2012;19: 503-508.
- Detection of circulating tumor cells in peripheral blood of heavily treated metastatic breast cancer patients
- Breast Cancer 2011; 18: 195-202.
- Availability of irinotecan in a second-line setting confers survival benefit to patients with advanced gastric cancer refractory to fluoropyrimidine-based regimens
- Oncol Lett 2011; 2: 247-251.
- Irinotecan monotherapy offers advantage over combination therapy with irinotecan plus cisplatin in second-line setting for treatment of advanced gastric cancer following failure of fluoropyrimidine-based regimens
- Oncol Lett 2011; 2: 241-245.
- A case of lymphocytic mastopathy requiring differential diagnosis from primary breast lymphoma
- Breast Cancer 2009; 16: 141-146.
- A selective cyclooxygenase-2 inhibitor prevents inflammation-related squamous cell carcinogenesis of the forestomach via duodenogastric reflux in rats
- Cancer 2009; 115: 454-464.
- Chemoprevention of glandular stomach carcinogenesis through duodenogastric reflux in rats by a COX-2 inhibitor
- Int J Cancer 2008; 123: 1491-1498.
研究協力英語論文
- Recurrence-free survival versus overall survival as a primary endpoint for studies of resected colorectal liver metastasis: a retrospective study and meta-analysis
- Lancet Oncol; 2022 DOI: https://doi.org/10.1016/S1470-2045(22)00506-X
- Multi-center clinical evaluation of streptozocin-based chemotherapy for advanced pancreatic neuroendocrine tumors in Japan: focus on weekly regimens and monotherapy
- Cancer Chemother Pharmacol 2018; 82: 661-668.